Form 4: Pfizer CEO Albert Bourla Reports Acquisition of Phantom Stock Units

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 18 phantom stock units through the company's Supplemental Savings Plan on May 31, 2024.

Summary

• On May 31, 2024, Albert Bourla, the Chairman and CEO of Pfizer Inc., acquired 18 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price of the phantom stock units was $28.66.
• Following the transaction, Bourla directly owns 668,712 shares.
• These units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of phantom stock units by the CEO can be seen as a positive sign of his confidence in the company, but it's a routine transaction.

Positives

• The acquisition of phantom stock units by the CEO demonstrates his continued investment in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. It provides transparency into the executive's investment in the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options, restricted stock units (RSUs), or phantom stock units to align executive interests with shareholder value.
• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize similar equity-based compensation plans for their executives.
• The specific terms and conditions of these plans vary, but the underlying goal is to incentivize long-term performance and retention.

Stakeholder Impact

• The acquisition of phantom stock units by the CEO could have a slightly positive impact on shareholder sentiment, as it signals his commitment to the company's success.

Key Dates